COYA
Coya Therapeutics Inc

1,124
Mkt Cap
$98.75M
Volume
141,971.00
52W High
$7.75
52W Low
$3.94
PE Ratio
-3.51
COYA Fundamentals
Price
$4.21
Prev Close
$4.27
Open
$4.29
50D MA
$4.71
Beta
0.97
Avg. Volume
126,447.47
EPS (Annual)
-$1.27
P/B
2.05
Rev/Employee
$993,219.13
$50.21
Loading...
Loading...
News
all
press releases
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·13h ago
News Placeholder
More News
News Placeholder
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...
Business Wire·3d ago
News Placeholder
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Monday...
MarketBeat·5d ago
News Placeholder
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)
Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Monday...
MarketBeat·5d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results
Coya Therapeutics (NASDAQ:COYA - Get Free Report) issued its earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of...
MarketBeat·5d ago
News Placeholder
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire·5d ago
News Placeholder
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday
Coya Therapeutics (NASDAQ:COYA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages
Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·22d ago
News Placeholder
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·24d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.